Hereditary angioedema in children and adolescents.

Hereditary angioedema is a genetic disease with autosomal dominant inheritance and, in most cases, caused by C1 inhibitor deficiency. Patients present with recurrent edema affecting sub-cutaneous and mucus membranes with variable onset and severity. More than 50% of patients may become symptomatic before 10 years of age. Family history can help with the diagnosis; however, approximately 25% of the cases are de novo mutations. Biochemical diagnosis should be delayed until after 1 year of age. Children were often excluded from advances in therapy for hereditary angioedema since most of the new medicines were tested in adults and thus excluded by the Food and Drug Administration (FDA) and other agencies for approval to be used in children. Treatment of attacks is available for the pediatric patient; however, barriers still exist for the use of long-term prophylaxis in young children. © 2022 Codon Publications. Published by Codon Publications.

[1]  J. Bernstein,et al.  Long‐term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study , 2021, Allergy.

[2]  A. Nicolas,et al.  Impact de l’angiœdème héréditaire sur les activités de la vie quotidienne, la sphère émotionnelle et la qualité de vie des patients , 2021, La Revue de Médecine Interne.

[3]  H. Iocca,et al.  Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study , 2021, Clinical and translational allergy.

[4]  W. Lumry,et al.  Triggers of Exacerbation in Chronic Urticaria and Recurrent Angioedema-Prevalence and Relevance. , 2021, The journal of allergy and clinical immunology. In practice.

[5]  J. Bernstein,et al.  Consensus on treatment goals in hereditary angioedema: a global Delphi initiative. , 2021, The Journal of allergy and clinical immunology.

[6]  K. Aggarwal,et al.  Physician and patient perspectives on the management of hereditary angioedema: a survey on treatment burden and needs. , 2021, Allergy and asthma proceedings.

[7]  T. Craig,et al.  Short-term prophylaxis for children and adolescents with hereditary angioedema. , 2021, Allergy and asthma proceedings.

[8]  L. Arruda,et al.  Hereditary angioedema: how to approach it at the emergency department? , 2021, Einstein.

[9]  J. Bernstein,et al.  Recognition, Evaluation, and Management of Pediatric Hereditary Angioedema. , 2021, Pediatric emergency care.

[10]  F. Minafra,et al.  The Challenges in the Follow-Up and Treatment of Brazilian Children with Hereditary Angioedema , 2021, International Archives of Allergy and Immunology.

[11]  Britta S. Möhl,et al.  Novel hereditary angioedema linked with a heparan sulfate 3-O-sulfotransferase 6 gene mutation. , 2021, The Journal of allergy and clinical immunology.

[12]  J. Pesquero,et al.  The Panorama of Primary Angioedema in the Brazilian Population. , 2020, The journal of allergy and clinical immunology. In practice.

[13]  T. Craig.  Triggers and short-term prophylaxis in patients with hereditary angioedema. , 2020, Allergy and asthma proceedings.

[14]  William H. Yang,et al.  Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. , 2020, The Journal of allergy and clinical immunology.

[15]  T. Machnig,et al.  Clinical features of genetically characterized types of hereditary angioedema with normal C1 inhibitor: a systematic review of qualitative evidence , 2020, Orphanet Journal of Rare Diseases.

[16]  J. Bernstein,et al.  US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. , 2020, The journal of allergy and clinical immunology. In practice.

[17]  B. Giannetti,et al.  Hereditary Angioedema Attack in Utero and Treatment of the Mother and Fetus , 2020, Mayo Clinic proceedings. Innovations, quality & outcomes.

[18]  A. Franzese,et al.  The experience of living with a chronic disease in pediatrics from the mothers’ narratives: The Clinical Interview on Parental Sense of Grip on the Disease , 2020, Health psychology open.

[19]  M. Margaglione,et al.  A myoferlin gain‐of‐function variant associates with a new type of hereditary angioedema , 2020, Allergy.

[20]  R. Krüger,et al.  Hereditary angioedema in children and adolescents – A consensus update on therapeutic strategies for German‐speaking countries , 2020, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[21]  G. Porebski,et al.  Life-threatening laryngeal attacks in hereditary angioedema patients. , 2020, Otolaryngologia polska = The Polish otolaryngology.

[22]  M. Cicardi,et al.  Short-term prophylaxis in patients with angioedema due to C1-inhibitor deficiency undergoing dental procedures: An observational study , 2020, PloS one.

[23]  S. Cichon,et al.  International consensus on the use of genetics in the management of hereditary angioedema. , 2020, The journal of allergy and clinical immunology. In practice.

[24]  M. López-Trascasa,et al.  SERPING1 mutation update: Mutation spectrum and C1 Inhibitor phenotypes , 2019, Human mutation.

[25]  M. Freda,et al.  Caregivers’ Sensemaking of Children’s Hereditary Angioedema: A Semiotic Narrative Analysis of the Sense of Grip on the Disease , 2019, Front. Psychol..

[26]  M. Levin,et al.  Fresh frozen plasma for on-demand hereditary angioedema treatment in South Africa and Iran , 2019, The World Allergy Organization journal.

[27]  William H. Yang,et al.  Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks. , 2019, The journal of allergy and clinical immunology. In practice.

[28]  I. Braenne,et al.  Hereditary angioedema cosegregating with a novel kininogen 1 gene mutation changing the N‐terminal cleavage site of bradykinin , 2019, Allergy.

[29]  A. Grumach,et al.  Assessment on hereditary angioedema burden of illness in Brazil: A patient perspective. , 2019, Allergy and asthma proceedings.

[30]  Moshe Y. Vardi,et al.  A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema , 2019, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[31]  K. Bork,et al.  Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[32]  J. Bernstein,et al.  Efficacy of recombinant human C1 esterase inhibitor across anatomic locations in acute hereditary angioedema attacks. , 2018, Allergy and asthma proceedings.

[33]  J. Bernstein,et al.  Hereditary angioedema from the patient's perspective: A follow-up patient survey. , 2018, Allergy and asthma proceedings.

[34]  R. Lockey,et al.  The international WAO/EAACI guideline for the management of hereditary angioedema—The 2017 revision and update , 2018, Allergy.

[35]  I. Braenne,et al.  Hereditary angioedema with a mutation in the plasminogen gene , 2018, Allergy.

[36]  S. Cichon,et al.  Hereditary Angioedema with Normal C1 Inhibitor and F12 Mutations in 42 Brazilian Families. , 2017, The journal of allergy and clinical immunology. In practice.

[37]  M. Margaglione,et al.  Mutation of the angiopoietin‐1 gene (ANGPT1) associates with a new type of hereditary angioedema , 2017, The Journal of allergy and clinical immunology.

[38]  W. Aberer,et al.  Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema. , 2017, The journal of allergy and clinical immunology. In practice.

[39]  J. Bernstein,et al.  Angioedema in the emergency department: a practical guide to differential diagnosis and management , 2017, International Journal of Emergency Medicine.

[40]  T. Machnig,et al.  Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema , 2017, Allergy & rhinology.

[41]  W. Lumry,et al.  Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility. , 2017, The journal of allergy and clinical immunology. In practice.

[42]  M. Triggiani,et al.  International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency , 2016, Allergy.

[43]  J. Bernstein,et al.  Management of Children With Hereditary Angioedema Due to C1 Inhibitor Deficiency , 2016, Pediatrics.

[44]  A. Pagnier,et al.  Hereditary angioedema with normal C1 inhibitor and factor XII mutation: a series of 57 patients from the French National Center of Reference for Angioedema , 2016, Clinical and experimental immunology.

[45]  T. Machnig,et al.  Efficacy of Different Medical Therapies for the Treatment of Acute Laryngeal Attacks of Hereditary Angioedema due to C1-esterase Inhibitor Deficiency. , 2016, The Journal of emergency medicine.

[46]  K. Bork,et al.  Hereditary angioedema with normal C1‐INH with versus without specific F12 gene mutations , 2015, Allergy.

[47]  K. Beusterien,et al.  Burden of Illness in Hereditary Angioedema: A Conceptual Model. , 2015, Acta dermato-venereologica.

[48]  M. Triggiani,et al.  Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group , 2014, Allergy.

[49]  K. Bork,et al.  Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective study. , 2011, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[50]  H. Longhurst.  Management of acute attacks of hereditary angioedema: potential role of icatibant , 2010, Vascular health and risk management.